5 matches for your search in the start-up spotlight
rss
Abselion started in 2018, at that time under the name HexagonFab, in a small corner of a laboratory at the University of Cambridge. We set out with the humble goal to make protein research simpler. Scientists should be able to pursue their passion for discovery and innovation, rather than spend ...
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base ...
Transine Therapeutics is developing a novel class of therapeutic RNAs that have the property to drive up protein expression with an unprecedented level of control and specificity: The SINEUP® platform. Our SINEUPs are designed to precisely bind to a target mRNA and boost expression of almost any ...
Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. By using microchip industry materials and techniques we are revolutionizing in vitro research on cell models to help create better medicines, ...
At Quench Bio we are discovering inhibitors of novel targets in innate immunity, the gasdermins. A central player in multiple pathways leading to inflammatory cell death, Gasdermin D acts as the executioner of pyroptosis and NETosis. By targeting this core node in innate immunity, we will inhibit ...
